Easterly Investment Partners LLC Has $1.63 Million Stock Position in Collegium Pharmaceutical, Inc. $COLL

Easterly Investment Partners LLC trimmed its holdings in shares of Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 31.7% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 35,131 shares of the specialty pharmaceutical company’s stock after selling 16,281 shares during the period. Easterly Investment Partners LLC owned approximately 0.11% of Collegium Pharmaceutical worth $1,627,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also recently bought and sold shares of the company. Federated Hermes Inc. raised its position in Collegium Pharmaceutical by 67.0% during the third quarter. Federated Hermes Inc. now owns 872 shares of the specialty pharmaceutical company’s stock valued at $31,000 after buying an additional 350 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its position in Collegium Pharmaceutical by 26.1% during the fourth quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock valued at $71,000 after buying an additional 318 shares during the period. Hantz Financial Services Inc. raised its position in Collegium Pharmaceutical by 137.7% during the third quarter. Hantz Financial Services Inc. now owns 1,714 shares of the specialty pharmaceutical company’s stock valued at $60,000 after buying an additional 993 shares during the period. EverSource Wealth Advisors LLC raised its position in Collegium Pharmaceutical by 744.9% during the second quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock valued at $73,000 after buying an additional 2,190 shares during the period. Finally, NewEdge Advisors LLC raised its position in Collegium Pharmaceutical by 304.6% during the second quarter. NewEdge Advisors LLC now owns 3,047 shares of the specialty pharmaceutical company’s stock valued at $90,000 after buying an additional 2,294 shares during the period.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on COLL. Truist Financial set a $58.00 price target on Collegium Pharmaceutical in a research report on Tuesday, February 10th. Wall Street Zen raised Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Saturday, May 9th. HC Wainwright reaffirmed a “buy” rating and issued a $60.00 target price on shares of Collegium Pharmaceutical in a research report on Friday, March 20th. Needham & Company LLC reaffirmed a “buy” rating and issued a $56.00 target price (up from $54.00) on shares of Collegium Pharmaceutical in a research report on Thursday, March 19th. Finally, Weiss Ratings lowered Collegium Pharmaceutical from a “buy (b-)” rating to a “hold (c+)” rating in a research report on Thursday, March 5th. Four investment analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $57.50.

Insider Activity

In other news, EVP David Dieter sold 13,976 shares of the company’s stock in a transaction dated Wednesday, March 18th. The stock was sold at an average price of $34.92, for a total transaction of $488,041.92. Following the completion of the sale, the executive vice president owned 77,071 shares in the company, valued at approximately $2,691,319.32. This represents a 15.35% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Company insiders own 1.85% of the company’s stock.

Collegium Pharmaceutical Stock Performance

COLL opened at $31.78 on Tuesday. The company has a market cap of $1.03 billion, a PE ratio of 15.58 and a beta of 0.76. The stock has a 50-day moving average of $34.03 and a 200-day moving average of $41.28. Collegium Pharmaceutical, Inc. has a 52-week low of $28.74 and a 52-week high of $50.79. The company has a debt-to-equity ratio of 2.47, a quick ratio of 1.62 and a current ratio of 1.71.

Collegium Pharmaceutical (NASDAQ:COLL) last released its quarterly earnings results on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.52 by $0.24. The company had revenue of $193.52 million during the quarter, compared to the consensus estimate of $184.47 million. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The firm’s revenue was up 8.9% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.49 EPS. As a group, equities research analysts forecast that Collegium Pharmaceutical, Inc. will post 6.76 earnings per share for the current fiscal year.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.